Trial CTRI/2020/04/024729
Publication Thakar A, Indian J Med Res, 2021
Primary outcome on the report: Drug tolerance, clinical and virological metrics. Toxicity assessment was carried out by direct verbal questioning and subsequent investigations as required. General well-being was assessed daily along with the evaluation of the breath-holding time and documentation of the NEWS on days 0, 3, 7 and 10. Nasal swabs were taken on days 0, 3, 7 and 10 and tested by real-time RT-PCR targeting the ORF1ab gene (BGI Genomics Co. Ltd., China) on Agilent AriaMx real-time PCR system.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.